Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290120 | 0.92 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL290119 | 0.92 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL23496246 | 0.91 | ALDH1A1 (0.47) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL21052552 | 0.91 | ALDH1A1 (0.47) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL21052386 | 0.89 | ALDH1A1 (0.40) | ALDH1A1CNR1CNR2 | |
| SCHEMBL20574219 | 0.88 | ADORA3 (0.48) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL23496243 | 0.88 | ADORA3 (0.48) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL21052406 | 0.88 | ALDH1A1 (0.41) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL21052407 | 0.88 | ALDH1A1 (0.41) | ALDH1A1CNR1CNR2MAPT | |
| SCHEMBL28460760 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2MGLLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| EP-3383380-B1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2023-01-04 | — | — | EP | disclosed |
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2021-06-17 | — | — | US | disclosed |
| EP-3720431-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2020-10-14 | — | — | EP | disclosed |
| CN-111712240-A | Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis | 巴斯夫股份公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2019-09-19 | — | — | US | disclosed |
| WO-2019111048-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2019-06-13 | — | — | WO | disclosed |
| US-20180346408-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H3, NR1H2 | ALDH1A1 162/4885CNR1 761/4885CNR2 495/4885 |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CNR1 743/4885CNR2 506/4885 |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | APOB, ALOX12, NR1H2 | ALDH1A1 417/4885CNR1 514/4885CNR2 491/4885 |
| US-20180346408-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | NR1H2, NR1H3, APOB | ALDH1A1 618/4885CNR1 542/4885CNR2 286/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CNR1 743/4885CNR2 506/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | ALDH1A1 162/4885CNR1 761/4885CNR2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.